Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vincent Pongia

Podiatrist, Primary Podiatric Medicine Coatesville, PA Doctor of Podiatric Medicine

NPI 1689687204 CMS profile 31387

213 Reeceville Rd Ste 13, Coatesville, PA 19320

Open in the dashboard

General payments

$3,360

161 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vincent Pongia of Coatesville, PA is reported in the CMS Open Payments database as having received $3,360 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Podiatrist, Primary Podiatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $216 11
2024 General $906 41
2023 General $746 34
2022 General $642 25
2021 General $241 13
2020 General $210 13
2019 General $399 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vincent Pongia
  • Podiatrist, Primary Podiatric Medicine median
  • Middle half of Podiatrist, Primary Podiatric Medicine
  • National median

In program year 2025, general payments to Vincent Pongia were reported at $216. Among 368 Podiatrist, Primary Podiatric Medicine profiles paid that year, the median was $232 and the middle half received between $88 and $586.

Show as a table
Year Vincent Pongia Podiatrist, Primary Podiatric Medicine median Middle half National median
2019 $399 $166 $51–$513 $163
2020 $210 $108 $33–$249 $114
2021 $241 $147 $52–$377 $132
2022 $642 $188 $66–$551 $149
2023 $746 $195 $70–$509 $160
2024 $906 $209 $59–$508 $164
2025 $216 $232 $88–$586 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Paratek Pharmaceuticals, Inc. $425 31 payments
  2. ConvaTec Inc. $407 9 payments
  3. Smith+Nephew, Inc. $380 22 payments
  4. Bioventus LLC $194 5 payments
  5. Aroa Biosurgery Incorporated $164 2 payments
  6. AbbVie, Inc. $162 8 payments
  7. GRT US Holding, Inc. $129 6 payments
  8. Horizon Therapeutics plc $121 8 payments
  9. Nevro Corp. $115 5 payments
  10. Tactile Systems Technology Inc $106 4 payments
  11. Other $1,158 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,358 160 payments
  2. Education $2 1 payment
Products named General payments · program years 2019–2025
  1. NUZYRA $425 31 payments
  2. INNOVAMATRIX AC $407 9 payments
  3. Qutenza $213 10 payments
  4. DALVANCE $178 9 payments
  5. COLLAGENASE SANTYL $107 6 payments
  6. KRYSTEXXA $106 7 payments
  7. GrafixPL $89 6 payments
  8. GRAFIX $89 6 payments
  9. Stravix $89 6 payments
  10. Flexitouch Plus $73 2 payments
  11. Other $1,847 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

418

Median for Podiatry: 160

Drug cost

$5,922

Median for Podiatry: $2,368

Branded share of claims

5.7%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 78 $2,203
Ketoconazole Generic 98 $2,167
Silver Sulfadiazine Generic 34 $334
Cephalexin Generic 58 $278
Terbinafine Hcl Generic 19 $216
Gabapentin Generic 15 $145
Methylprednisolone Generic 27 $112
Ssd Silver Sulfadiazine Brand 11 $102
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 13 $95
Tramadol Hcl Generic 29 $93

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$266,050

Of which drugs: $47,253

Medicare patients

462

Average age 75

Services billed

21,198

229 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 48%
Arthritis 46%
Chronic kidney disease 39%
Ischemic heart disease 34%
Atrial fibrillation 25%
Depression 25%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Capsaicin 8% patch, per square centimeter J7336 Office 11 18,200 $47,253

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $149
$149 — —
DALVANCE
  • AbbVie, Inc. $55
$55 — —
Qutenza
  • Averitas Pharma Inc. $47
$47 — 18,200
KRYSTEXXA
  • Amgen Inc. $22
$22 — —
Tirosint
  • IBSA Pharma Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Primary Podiatric Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record